Summary

Location
at San Diego, California and other locations
Dates
study started
completion around

Description

Summary

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

Official Title

The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens

Keywords

T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, Chronic Lymphoproliferative Disorder of NK Cells, Aggressive NK-cell Leukemia, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Adult T-cell Leukemia/Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Enteropathy-associated T-cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Breast Implant-Associated Anaplastic Large Cell Lymphoma, 23-190, Memorial Sloan Kettering Cancer Center, T-cell Lymphoma Master Repository, TCLMR, Mycoses, Epstein-Barr Virus Infections, Lymphoma, Leukemia, Non-Hodgkin Lymphoma, Lymphoma, T-Cell, Peripheral, T-Cell Leukemia, Adult T-Cell Leukemia-Lymphoma, Lymphoma, Large-Cell, Anaplastic, Lymphoma, T-Cell, Cutaneous, Extranodal NK-T-Cell Lymphoma, Prolymphocytic Leukemia, Large Granular Lymphocytic Leukemia, Leukemia, Prolymphocytic, T-Cell, Lymphoproliferative Disorders, Immunoblastic Lymphadenopathy, Panniculitis, Hydroa Vacciniforme, Aggression

Eligibility

You can join if…

  • Written informed consent
  • Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.
  • Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):
    • T-cell prolymphocytic leukemia
    • T-cell large granular lymphocytic leukemia
    • Chronic lymphoproliferative disorder of NK cells
    • Aggressive NK-cell leukemia
    • Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
    • Chronic active EBV infection of T- and NK-cell type, systemic form
    • Hydroa vacciniforme-like lymphoproliferative disorder
    • Adult T-cell leukemia/lymphoma
    • Extranodal NK/T-cell lymphoma, nasal type
    • Enteropathy-associated T-cell lymphoma
    • Monomorphic epitheliotropic intestinal T-cell lymphoma
    • Intestinal T-cell lymphoma, not otherwise specified (NOS)
    • Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
    • Hepatosplenic T-cell lymphoma
    • Subcutaneous panniculitis-like T-cell lymphoma
    • Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
    • Sézary syndrome
    • Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
    • Primary cutaneous Gamma-Delta T-cell lymphoma
    • Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
    • Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
    • Peripheral T-cell lymphoma, not otherwise specified
    • Angioimmunoblastic T-cell lymphoma
    • Follicular T-cell lymphoma
    • Nodal peripheral T-cell lymphoma with TFH phenotype
    • Anaplastic large cell lymphoma, ALK-positive
    • Anaplastic large cell lymphoma, ALK-negative
    • Breast-implant associated anaplastic large cell lymphoma.
  • NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.

You CAN'T join if...

  • Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
  • Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.

Locations

  • UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only) not yet accepting patients
    San Diego California 92103 United States
  • City of Hope Cancer Center (Data collection only) not yet accepting patients
    Duarte California 91010 United States
  • Memorial Sloan Kettering at Basking Ridge (All protocol activities) accepting new patients
    Basking Ridge New Jersey 07920 United States
  • Memorial Sloan Kettering Monmouth (All protocol activities) accepting new patients
    Middletown New Jersey 07748 United States

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Memorial Sloan Kettering Cancer Center
Links
Memorial Sloan Kettering Cancer Center
ID
NCT05978141
Study Type
Observational [Patient Registry]
Participants
Expecting 1000 study participants
Last Updated